History of LDN
Low dose naltrexone (LDN) has been utilized for over two decades in individuals with autoimmune disorders.
Historically, naltrexone has been prescribed at a 50mg dose to aid patients in recovering from addiction to heroin, alcohol, and other opiate drugs. However, in 1985, Dr. Bihari discovered that naltrexone at a much lower dose (3mg at bedtime) had profound effects on the immune system.
Introduction to LDN and Its Mechanism of Action
When LDN is taken at bedtime, it binds to opioid receptors in the brain and various immune cells, temporarily blocking the attachment of endorphins to these receptors. This triggers the body to produce more endorphins, which play a crucial role in orchestrating the activity of stem cells, macrophages, natural killer cells, T and B cells, and other immune cells.
LDN also helps prevent excessive immune system activity, which is a key factor in autoimmune disorders, and reduces the release of inflammatory and neurotoxic chemicals in the brain.
Clinical Applications of LDN
Studies have shown that LDN can be beneficial in treating various conditions, including ALS, Alzheimer’s disease, autism, celiac disease, Crohn’s disease, fibromyalgia, inflammatory bowel disease, lupus, multiple sclerosis, Parkinson’s disease, psoriasis, rheumatoid arthritis, ulcerative colitis, and Lyme disease.
Valiant Compounding Pharmacy can compound LDN in different strengths. While it is typically administered as an oral capsule at a dose of 1.5mg to 4.5mg, we can also formulate LDN into a transdermal cream or an oral suspension. LDN can also be compounded into a dosage form that is free of fillers, including gluten, dyes, lactose, sugars, and other additives.
